期刊文献+

Chinese Expert Proposal on the Diagnosis and Management of Pemphigus Vulgaris (2020) 被引量:2

原文传递
导出
摘要 Pemphigus vulgaris(PV)is a life-threatening autoimmune bullous disease that causes blisters and erosions on the skin and mucous membranes to standardize the diagnosis and treatment of PV,Chinese experts in this field were invited to make recommendations which are presented in this article.Pemphigus vulgaris can be divided into cutaneous mucous type,cutaneous type and mucous mucous dominant type according to the different clinical manifestations.The pathological manifestations of PV are acantholysis above the basal layer.The diagnosis of PV and the assessment of the severity of the disease are made in accordance with the clinical manifestations,histopathological features,immunofluorescence assay results,and detection of pathogenic serum antibodies.The first-line treatment of PV comprises systemic glucocorticoids.Early combination with immunosuppressive agents or rituximab is recommended for moderate and severe PV.Intravenous immunoglobulin administration is recommended for patients being treated with rituximab.Plasma exchange and stem cell transplantation can be performed if necessary.During the course of therapy,the disease activity should be closely monitored,and actions should be taken to prevent adverse reactions.
出处 《International Journal of Dermatology and Venereology》 2020年第3期148-155,共8页 国际皮肤性病学杂志(英文)
  • 相关文献

参考文献1

二级参考文献16

  • 1Narbutt J, Boncela J, Smolarczyk K, et al. Pathogenic activity of circulating anti-desmoglein-3 autoantibodies isolated from pemphigus vulgaris patients[J]. Arch Med Sci, 2012, 8(2): 347- 356.
  • 2Anand V, Khandpur S, Sharma VK, et al. Utility of desmoglein ELISA in the clinical correlation and disease monitoring of pemphigus vulgaris[J], J Eur Acad Dermatol Venereol, 2012, 26 (11): 1377-1383.
  • 3Abasq C, Mouquet H, Gilbert D, et aI. ELISA testing of antidesmoglein 1 and 3 antibodies in the management of pemphigus [J]. Arch Dermatol, 2009, 145(5): 529-535.
  • 4Zhong S, Qiu YF, Han BB, et al. Detection of serum desmoglein antibody level using enzyme-linked immunosorbent assay (ELISA) for monitoring disease activity in patients with pemphigus vulgaris [J]. Beijing Da Xue Xue Bao, 2011, 43 (3): 414-415.
  • 5Ikeda S, Imamura S, Hashimoto I, et al. History of the establishment and revision of diagnostic criteria, severity index and therapeutic guidelines for pemphigus in Iapan[J]. Arch Dermatol Res, 2003, 295( 1 ): SI2-S16.
  • 6Jamora MJ, Jiao D, Bystryn JC. Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgaris [J]. J Am Acad Dermatol, 2003, 48(6): 976-977.
  • 7Sharma VK, Prasad HR, Khandpur S, et al. Evaluation of desmoglein enzyme-linked immunosorbent assay (ELISA) in Indian patients with pemphigus vulgaris [J]. Int J Dermatol, 2006, 45 (5): 518- 522.
  • 8Harman KE, Gratian MJ, Bhogal BS, et al. A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype [J]. Br J Dermatol, 2000, 143(2): 343-348.
  • 9Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins [J]. J Immunol, 1997, 159(4): 2010-2017.
  • 10Cheng SW, Kobayashi M, Kinoshita-Kuroda K, et al. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 [J]. Br J Dermatol, 2002, 147(2): 261-265.

共引文献10

同被引文献5

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部